Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for Portopulmonary Hypertension
NCT01733095Phase 2Withdrawn
- Sponsor
- Medical University of Graz
- Start
- Jul 2012
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambrisentan in portopulmonary hypertension (POPH), sponsored by Medical University of Graz. Primary endpoint: Pulmonary Vascular Resistance at 24 weeks. Planned start Jul 2012; status: withdrawn.
02
Drugs
ambrisentan
03
Conditions
portopulmonary hypertension (POPH)
Beyond the preview
Go deeper on NCT01733095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01733095.